Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Equity Ratio (2016 - 2025)

Ligand Pharmaceuticals' Equity Ratio history spans 16 years, with the latest figure at 0.64 for Q3 2025.

  • For Q3 2025, Equity Ratio fell 26.96% year-over-year to 0.64; the TTM value through Sep 2025 reached 0.64, down 26.96%, while the annual FY2024 figure was 0.88, 0.96% down from the prior year.
  • Equity Ratio for Q3 2025 was 0.64 at Ligand Pharmaceuticals, down from 0.87 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.89 in Q2 2024 and bottomed at 0.58 in Q1 2021.
  • The 5-year median for Equity Ratio is 0.8 (2023), against an average of 0.78.
  • The largest annual shift saw Equity Ratio rose 24.63% in 2022 before it dropped 26.96% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.63 in 2021, then rose by 23.79% to 0.78 in 2022, then grew by 13.65% to 0.89 in 2023, then dropped by 0.96% to 0.88 in 2024, then fell by 27.03% to 0.64 in 2025.
  • Per Business Quant, the three most recent readings for LGND's Equity Ratio are 0.64 (Q3 2025), 0.87 (Q2 2025), and 0.88 (Q1 2025).